- Home
- JTAI vs PPBT Comparison
JTAI vs PPBT Comparison
Compare JTAI & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JTAI | PPBT |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | Israel |
| Employees | 8 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | JTAI | PPBT |
|---|---|---|
| Price | $9.04 | $2.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $80.00 | $30.00 |
| AVG Volume (30 Days) | ★ 161.8K | 40.1K |
| Earning Date | 05-15-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $0.41 |
| 52 Week High | $10.41 | $5.18 |
Technical Indicators
Market Signals| Indicator | JTAI | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 66.84 | 37.59 |
| Support Level | $6.03 | $0.57 |
| Resistance Level | $9.24 | $4.39 |
| Average True Range (ATR) | 0.69 | 0.31 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 88.29 | 29.84 |
Price Performance
Historical ComparisonAbout JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.